These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 24183076)

  • 1. [Evaluating the efficacy of a new drug].
    Berbis J; Alessandrini M; Karsenty G; Auquier P
    Prog Urol; 2013 Nov; 23(15):1208-12. PubMed ID: 24183076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug research: from the idea to the product.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of early efficacy endpoints for proof-of-concept trials.
    Chen C; Sun L; Li CL
    J Biopharm Stat; 2013 Mar; 23(2):413-24. PubMed ID: 23437947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innovative approaches in drug development.
    Chang M; Kenley S; Bull J; Chiu YY; Wang W; Wakeford C; McCarthy K
    J Biopharm Stat; 2007; 17(5):775-89. PubMed ID: 17885865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development.
    De Ridder F
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):235-41. PubMed ID: 15733220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From translational research to a large randomized clinical trial: a long and streanuous way from bench to bedside.
    Sakamoto J; Morita S
    Nagoya J Med Sci; 2007 Jan; 69(1-2):9-16. PubMed ID: 17378175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Designing phase III or IV trials for vaccines: choosing between individual or cluster randomised trial designs.
    Vaucher P
    Vaccine; 2009 Mar; 27(13):1928-31. PubMed ID: 19368773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial design in metastatic breast cancer: a commentary.
    Levine M
    Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malaria vaccine trial endpoints - bridging the gaps between trial design, public health and the next generation of vaccines.
    O'Meara WP; Lang T
    Parasite Immunol; 2009 Sep; 31(9):574-81. PubMed ID: 19691560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analyses and adaptive group sequential designs in the clinical development process.
    Jennison C; Turnbull BW
    J Biopharm Stat; 2005; 15(4):537-58. PubMed ID: 16022162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trials.
    Bennett CL; George SL; Vose JM; Nemunaitis JJ; Armitage JL; Armitage JO; Gorin NC; Gulati SC
    Stem Cells; 1995 Jul; 13(4):414-20. PubMed ID: 7549900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
    Taylor DJ; Grobler A; Abdool Karim SS
    Clin Trials; 2012 Aug; 9(4):377-84. PubMed ID: 22610168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy data.
    Heller G; Kattan MW; Scher HI
    Med Decis Making; 2007; 27(4):380-6. PubMed ID: 17761958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect and efficacy--on the function of models in controlled phase III trials and the need for prospective pharmacoepidemiological studies.
    Winterer G; Herrmann WM
    Pharmacopsychiatry; 1996 Jul; 29(4):135-41; discussion 142-3. PubMed ID: 8858712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
    Kikuchi T; Gittins J
    Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmarketing evaluations help determine contraceptive safety, efficacy.
    Netw Res Triangle Park N C; 1988; 9(2):1-2, 7. PubMed ID: 12280950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.